Eight years after biosimilar drugs were introduced to the prescription drug market, researchers from the USC Schaeffer Center have studied the cancer drug trastuzumab (Herceptin) and five similar medications as an example of biosimilars’ potential to reduce drug prices, including biologics.

The findings show that competition among the medications reduces the costs in a similar cause-and-effect process to the way generic drugs reduce the price of their name-brand counterparts.

The study — published in Health Affairs — is one of the first to look at several biosimilar competitors in terms of U.S. market share, price, and physician prescribing.

To read the full story, click here.